Entity

Time filter

Source Type

Burlingame, CA, United States

Nuccitelli R.,Bio Electro Med Corporation | Tran K.,Bio Electro Med Corporation | Athos B.,Bio Electro Med Corporation | Kreis M.,Bio Electro Med Corporation | And 5 more authors.
Biochemical and Biophysical Research Communications | Year: 2012

When skin tumors are exposed to non-thermal, low energy, nanosecond pulsed electric fields (nsPEF), apoptosis is initiated both in vitro and in vivo. This nanoelectroablation therapy has already been proven effective in treating subdermal murine allograft tumors. We wanted to determine if this therapy would be equally effective in the treatment of autochthonous BCC tumors in Ptch1+/-K14-Cre-ER p53 fl/fl mice. These tumors are similar to human BCCs in histology [2,20] and in response to drug therapy [19]. We have treated 27 BCCs across 8 mice with either 300 pulses of 300ns duration or 2700 pulses of 100ns duration, all at 30kV/cm and 5-7 pulses per second. Every nsPEF-treated BCC began to shrink within a day after treatment and their initial mean volume of 36±5 (SEM) mm3 shrunk by 76±3% over the ensuing two weeks. After four weeks, they were 99.8% ablated if the size of the treatment electrode matched the tumor size. If the tumor was larger than the 4mm wide electrode, multiple treatments were needed for complete ablation. Treated tumors were harvested for histological analysis at various times after treatment and exhibited apoptosis markers. Specifically, pyknosis of nuclei was evident as soon as 2days after nsPEF treatment, and DNA fragmentation as detected via TUNEL staining was also evident post treatment. Nanoelectroablation is effective in triggering apoptosis and remission of radiation-induced BCCs with a single 6min-long treatment of 2700 pulses. © 2012 Elsevier Inc. Source

Discover hidden collaborations